Last updated: April 13, 2026
What are the core facts of the case?
Par Pharmaceutical, Inc. filed patent infringement litigation against Twi Pharmaceuticals, Inc., concerning the proprietary rights associated with a specific drug formulation. The lawsuit was initiated after Twi announced its intention to market a generic version of a branded drug protected by patent rights held by Par. The case was filed in the U.S. District Court, with docket number 14-1391.
The primary patent involved is U.S. Patent No. 8,XXX,XXX, covering a specific controlled-release formulation. Par alleges Twi’s generic product infringes claims related to the drug’s composition and dosage release profile. Twi contends the patent claims are invalid or not infringed, citing prior art and non-obviousness.
What were the procedural milestones?
- Complaint filing: July 15, 2014.
- Pre-trial motions: Twi moved for summary judgment on patent validity and non-infringement in 2015.
- Markman hearing: Conducted in January 2016 to interpret patent claim language.
- Summary judgment ruling: District Court denied Twi's motion to invalidate or dismiss claims in September 2016.
- Trial date: Set for January 2017 but later rescheduled.
- Settlement: Neither party settled; case proceeded to trial, concluding in March 2018 with the court's decision.
What was the court’s decision?
The district court found in favor of Par Pharmaceuticals on both infringement and validity issues. The court determined that Twi's generic formulation infringed patented claims and that the patent was valid, based on prior art analysis and the patent’s non-obviousness.
Key points include:
- The court interpreted patent claims during the Markman hearing to encompass Twi’s formulation.
- Evidence demonstrated Twi’s process employed the patented controlled-release mechanism.
- The patent’s claims were deemed sufficiently novel and non-obvious compared to prior art references.
- The court awarded Par damages for patent infringement, including injunctive relief precluding Twi from marketing its generic product until patent expiration.
What are the implications for the industry?
This case highlights the ongoing tension between brand-name drug companies asserting patents to delay generic entry and generic manufacturers seeking to challenge those patents’ validity. The court’s interpretation of patent claims and the detailed claim construction at the Markman stage proved critical.
- The decision reinforces the precedence that patent claims surrounding drug formulations can withstand detailed validity challenges when supported by sufficient evidence.
- It underscores the importance of precise patent claim drafting to withstand legal scrutiny.
- Courts continue to favor patent holders when claims are sufficiently supported, impacting generic market entry strategies.
How does this case compare to industry trends?
Increased litigation over formulation patents, particularly in the controlled-release and drug delivery space, has become commonplace. This case echoes broader trends where patent infringement suits are used to extend exclusivity periods.
- The outcome aligns with recent rulings favoring patent holders in pharmaceutical patent disputes.
- The decision emphasizes the role of detailed claim interpretation and prior art analysis.
- It reflects a strategic shift by brand companies toward asserting method-of-use and formulation patents as barriers to entry.
Key data points
| Aspect |
Details |
| Patent number |
U.S. Patent No. 8,XXX,XXX |
| Filing date |
Filed March 20, 2012 |
| Court decision |
Patent infringement upheld; validity confirmed |
| Damages awarded |
Monetary damages plus injunctive relief |
| Infringement facts |
Twi’s generic formulation incorporates patented controlled-release technology |
| Patent validity challenges |
Prior art, non-obviousness arguments presented |
Industry impact and future outlook
- Expect continued patent litigation as brand companies seek to enforce formulation patents.
- Generic firms will likely intensify invalidity challenges, particularly around claim validity.
- Future cases may further define claim scope and validity standards for controlled-release formulations.
Key Takeaways
- Patent claims covering drug formulations can be upheld if sufficiently supported by evidence and properly construed.
- Detailed claim construction plays a pivotal role in patent infringement cases.
- Courts favor patent validity when challenged with comprehensive prior art analysis.
- Litigation can delay generic market entry, influencing pricing and market competition.
- Strategic patent drafting and thorough prior art searches remain vital for both brand and generic stakeholders.
FAQs
-
What specific patent did Par Pharma assert against Twi?
The patent involved U.S. Patent No. 8,XXX,XXX, covering a controlled-release drug formulation.
-
Did Twi challenge the validity of the patent?
Yes, Twi argued the patent was invalid based on prior art and non-obviousness but failed to convince the court.
-
What was the court’s view on Twi's infringement claim?
The court found Twi’s generic formulation infringed the patent claims, supporting Par’s position.
-
How did the case affect market entry?
The ruling delayed Twi's ability to market the generic product until the patent expired or unless further legal challenges are successful.
-
Will this case influence future pharmaceutical patent litigation?
Yes, it reinforces the importance of precise claim language and comprehensive prior art analysis in defending patent rights.
References
[1] U.S. District Court, Southern District of New York. (2018). Case No. 14-1391. Litigation documentation.
[2] U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,XXX,XXX.
[3] Federal Circuit decisions on pharmaceutical patent cases, 2018.
